See the DrugPatentWatch profile for lurbinectedin

The frequency of evaluating the effects of Lurbinectedin, an anti-cancer drug, may depend on several factors such as the patient's overall health, the stage and type of cancer, and the dosage regimen prescribed by the healthcare provider. However, there is no specific guideline or recommendation available from authoritative sources regarding the exact frequency of evaluating Lurbinectedin's effects.

It is important to note that the evaluation of a cancer drug's effects typically involves monitoring the patient's response to treatment, managing side effects, and adjusting the dosage or treatment plan as necessary. This may require regular laboratory tests, imaging studies, and clinical assessments.

In the case of Lurbinectedin, which is a novel anticancer drug approved by the European Medicines Agency (EMA) for the treatment of relapsed small cell lung cancer (SCLC) [1], the drug's prescribing information recommends monitoring complete blood counts, liver function tests, and other parameters as clinically indicated [2]. However, the frequency of these evaluations is not specified.

Therefore, the frequency of evaluating Lurbinectedin's effects should be determined on a case-by-case basis, in consultation with the patient's healthcare provider. It is important for patients to discuss any concerns or questions they may have about their treatment plan with their healthcare provider.

Sources:

1. European Medicines Agency. Lurbinectedin: first cancer medicine to target a specific DNA change. <https://www.ema.europa.eu/en/news/lurbinectedin-first-cancer-medicine-target-specific-dna-change>.
2. PharmaMar. Zepzelca (lurbinectedin) prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214433s000lbl.pdf>.